Recombinant
tissue-type plasminogen activator (rt-PA) was produced in Escherichia coli cells in order to obtain an
unglycosylated rt-PA (
BM 06.021) with increased thrombolytic potency due to altered pharmacokinetic properties. The pharmacokinetics were studied in rabbits upon
intravenous infusion of 200 kU/kg over 30 min. The thrombolytic dose-response effects were evaluated in a rabbit model with 125I-labeled venous thrombi upon
intravenous infusion over 4 h. The thrombolytic effects after intravenous bolus injection of 200 kU/kg
BM 06.021 were investigated in a canine model of coronary artery
thrombosis. All studies were performed comparing
BM 06.021 with glycosylated rt-PA (
alteplase).
BM 06.021 demonstrated a longer (p less than 0.05) half-life (5.6 +/- 2.6 vs. 2.1 +/- 0.3 min) and a lower (p less than 0.05) clearance rate (7.5 +/- 0.8 vs. 22.2 +/- 3.1 ml.min-1.kg-1) than
alteplase in rabbits upon
intravenous infusion. The dose-response curve of
BM 06.021 for thrombolysis in a rabbit model of jugular vein
thrombosis was located to the left of that for
alteplase with a 2.1-fold lower effective dose of 50% thrombolysis (ED50) of
BM 06.021 (207 vs. 436 kU/kg). Intravenous bolus injection of 200 kU/kg
BM 06.021 induced the same reperfusion rate (4/6) as
intravenous infusion of 800 kU/kg
alteplase over 90 min in a canine model of coronary artery
thrombosis. The residual
thrombus wet weight did not significantly differ between
BM 06.021 and
alteplase (5.7 +/- 1.8 vs. 6.3 +/- 1.1 mg). The results indicate that
unglycosylated rt-PA (
BM 06.021) has a higher in vivo thrombolytic potency than glycosylated rt-PA (
alteplase).(ABSTRACT TRUNCATED AT 250 WORDS)